Latest Clinical Trials
Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Sep 16, 2026)
PHASE2 Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma Hackensack Meridian Health NA
RECRUITING
(Sep 1, 2026)
PHASE1 A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant Fondazione EMN Italy Onlus NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma Hackensack Meridian Health NA
RECRUITING
(Sep 1, 2026)
PHASE2 Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma University of Washington NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone) EMN Trial Office S.r.l. Impresa Sociale NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE2 A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma BeOne Medicines NA
RECRUITING
(Sep 1, 2026)
PHASE1, PHASE2 A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) Bristol-Myers Squibb NA
ACTIVE NOT RECRUITING
(Sep 1, 2026)
PHASE3 Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma University of Chicago NA
RECRUITING
(Sep 1, 2026)
PHASE2 Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse National Cancer Institute (NCI) NA
RECRUITING
(Sep 1, 2026)
PHASE2 A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) Regeneron Pharmaceuticals NA
RECRUITING
(Sep 1, 2026)
PHASE3 Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma Hoffmann-La Roche NA
RECRUITING
(Sep 1, 2026)
PHASE3 Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy National Cancer Institute (NCI) NA
NOT YET RECRUITING
(Aug 26, 2026)
PHASE1 Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma Academic and Community Cancer Research United NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE2 A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma Janssen Research & Development, LLC NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 A Study of Daratumumab Janssen Research & Development, LLC NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE3 A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma K36 Therapeutics, Inc. NA
RECRUITING
(Aug 1, 2026)
PHASE1 A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma Pfizer NA
ACTIVE NOT RECRUITING
(Aug 1, 2026)
PHASE1 SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Roswell Park Cancer Institute NA
RECRUITING
(Aug 1, 2026)
PHASE1 Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease Roswell Park Cancer Institute NA
RECRUITING
(Aug 1, 2026)
PHASE2 Treatment of Antibody-Mediated Rejection (ABMR) With CarBel National Institute of Allergy and Infectious Diseases (NIAID) NA
RECRUITING
(Aug 1, 2026)
PHASE1 A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation Washington University School of Medicine NA
RECRUITING
(Aug 1, 2026)
PHASE1 Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment National Cancer Institute (NCI) NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma Natalie Callander NA
RECRUITING
(Aug 1, 2026)
PHASE1, PHASE2 Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial National Cancer Institute (NCI) NA
RECRUITING
(Aug 1, 2026)
PHASE2 Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma CellCentric Ltd. NA
RECRUITING
(Aug 1, 2026)
PHASE3 CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma National Cancer Institute (NCI) NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1 Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL) European Myeloma Network B.V. NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE3 Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma Wake Forest University Health Sciences NA
ACTIVE NOT RECRUITING
(Jul 1, 2026)
PHASE1, PHASE2 Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma Hackensack Meridian Health NA
SUSPENDED
(Jul 1, 2026)
PHASE1, PHASE2 A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma AbbVie NA
NOT YET RECRUITING
(Jul 1, 2026)
PHASE3 A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation Memorial Sloan Kettering Cancer Center NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM Andrew Yee, MD NA
ACTIVE NOT RECRUITING
(Jun 1, 2026)
PHASE2 A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations AbbVie NA
RECRUITING
(Jun 1, 2026)
PHASE1, PHASE2 KCD (Carfilzomib/Cyclophosphamide/Dexamethasone) Regimen for the Treatment of Newly Diagnosed POEMS Syndrome Shanghai Changzheng Hospital NA
RECRUITING
(Jun 1, 2026)
PHASE2 Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone Universitätsklinikum Hamburg-Eppendorf NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia Christian Buske NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 KRDI in Transplant-Eligible MM Massachusetts General Hospital NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide PETHEMA Foundation NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1, PHASE2 COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide University of Alabama at Birmingham NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE1, PHASE2 Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial Mayo Clinic NA
ACTIVE NOT RECRUITING
(May 1, 2026)
PHASE2 Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma Roswell Park Cancer Institute NA
WITHDRAWN
(May 1, 2026)
PHASE1 Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma. Mario Boccadoro NA
COMPLETED
(Apr 1, 2026)
PHASE2 Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma University Hospital, Lille NA
COMPLETED
(Apr 1, 2026)
PHASE2 Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction University Hospital, Toulouse NA
COMPLETED
(Apr 1, 2026)
PHASE2 Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma University of Chicago NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE2 Carfilzomib and Belatacept for Desensitization National Institute of Allergy and Infectious Diseases (NIAID) NA
ACTIVE NOT RECRUITING
(Apr 1, 2026)
PHASE1, PHASE2 Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer City of Hope Medical Center NA
RECRUITING
(Apr 1, 2026)
PHASE1 A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 Hackensack Meridian Health NA
COMPLETED
(Mar 1, 2026)
PHASE2 Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma University of Chicago NA
COMPLETED
(Mar 1, 2026)
PHASE2 Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma Thomas Martin, MD NA
COMPLETED
(Mar 1, 2026)
PHASE1 Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma University of Colorado, Denver NA
ACTIVE NOT RECRUITING
(Mar 1, 2026)
PHASE2 
